Fig. 4: DNA sequencing results for NEC-like SMARCA4/ARID1A tumors and outcome analysis of sinonasal undifferentiated carcinoma (SNUC) DNA methylation classes.
From: DNA methylation-based classification of sinonasal tumors
A The oncoprint plot shows tumor mutation burden (TMB) and recurrent mutations from whole exome sequencing or next generation panel sequencing (NGS). Potential treatment options and their respective evidence levels according to the classification from the Cancer Genome Interpreter website are shown in the panel below. B Overall survival Kaplan–Meier curve comparing disease-specific survival rates in different SNUC DNA methylation classes. The tables below show the number of patients at risk at different time points as well as a pairwise test for significance using the log-rank test. Patients with tumors from the SMARCB1 class had significantly worse survival compared to adenoid cystic carcinoma (ACC; p = 0.004), NEC-like IDH2 (p = 0.012) and NEC-like SMARCA4/ARID1A (p < 0.001) tumors. There was no significant difference between tumors from the NEC-like SMARCA4/ARID1A and ACC (p = 0.163) and NEC-like IDH2 (p = 0.168) class as well as between ACC and NEC-like IDH2 tumors (p = 0.950). NEC neuroendocrine carcinoma.
